Get the Stockscreener App
13.78
0.97%
-0.135
Vicore Pharma Holding Ab Adr stock is traded at $13.78, with a volume of 23,489.
It is down -0.97% in the last 24 hours and up +0.00% over the past month.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
See More
Previous Close:
$13.91
Open:
$13.596
24h Volume:
23,489
Relative Volume:
2.25
Market Cap:
$3.88B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$13.09
$14.01
1-Week Range:
$13.09
$17.80
52-Week Range:
$13.09
$17.80
Vicore Pharma Holding Ab Adr Stock (VCRE) Company Profile
Name
Vicore Pharma Holding Ab Adr
Sector
Industry
Phone
-
Address
-
Compare VCRE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCRE
Vicore Pharma Holding Ab Adr
|
13.78 | 3.88B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vicore Pharma Holding Ab Adr Stock (VCRE) Latest News
Free cash flow per share of Vicore Pharma Holding AB Sponsored ADR – FWB:6Y40 - TradingView
Total revenue of Vicore Pharma Holding AB Sponsored ADR – FWB:6Y40 - TradingView
Total operating expenses of Vicore Pharma Holding AB Sponsored ADR – FWB:6Y40 - TradingView
Vicore Pharma Holding AB Sponsored ADR Earnings and Revenue – FWB:6Y40 - TradingView
VCRE|Vicore Pharma Holding AB ADR|Price:14.124|Chg%:-0.901 - TradingKey
Citi named depositary bank for Vicore Pharma’s US shares - scanx.trade
TradingKey - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
Vicore Pharma Holding AB ADR (VCRE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vicore Pharma Holding AB ADR (VCRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vicore Pharma Holding AB ADR (VCRE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vicore Pharma Holding AB ADR - TradingKey
Vicore Pharma Holding AB ADR (VCRE) Institutional Confidence - TradingKey
Citibank Announces $1.5 Billion Redemption of 4.929% Notes Due 2026 and $1 Billion Redemption of Floating Rate Notes Due 2026 - Business Wire
Vicore Pharma Pursues US Dual Listing, Files Registration Statement with the SEC - ACCESS Newswire
Citi Announces 2026 Investor Day - Business Wire
Citi Appointed as Depositary Bank for Rightmove Plc’s ADR Program - Business Wire
Citigroup Reports First Quarter 2026 Results - Business Wire
C Stock Price | Analyst Target 152.00 & Strong Buy Consensus - eToro
Vicore Pharma Holding Ab Adr Stock (VCRE) Financials Data
There is no financial data for Vicore Pharma Holding Ab Adr (VCRE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):